Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation

American Journal of Hematology

Volumn 78, Issue 4, 2005, Pages 265-274

  Pavletic, Steven Z ^a,c   Smith, Lynette M ^b   Bishop, Michael R ^c   Lynch, James C ^b   Tarantolo, Stefano R ^a   Vose, Julie M ^a   Bierman, Philip J ^a   Hadi, Abdul ^a   Armitage, James O ^a   Kessinger, Anne ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Chronic; Graft versus host; Stem cell transplantation

Indexed keywords

ETOPOSIDE;

ACUTE DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC DISEASE; DEATH; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INCIDENCE; LIVER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RISK ASSESSMENT; SURVIVAL; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RISK FACTORS; SKIN; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20144389614     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20275     Document Type: Article

References (33)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
2. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. N Engl J Med 1981;304:1529-1533.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
4. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406-414.
5. Farag SS. Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant 2004;33:569-577.
6. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51.
7. Schulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
8. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001;97:1219-1226.
9. Ottinger HD, Beelen DW, Schuelen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-2779.
10. Pavletic ZS, Bishop MR, Tarantolo SR, et al. Hematopoietic recovery after allogeneic blood stem cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997;15:1608-1616.
11. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001;98:2900-2908.
12. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte-colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998;92:215-222.
13. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997;89:1629-1634.
14. Ageitos AG, Varney ML, Bierman PJ, Vose JM, Warkentin PI, Talmadge JE. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant 1999;23:63-69.
15. Joshi SS, Lynch JC, Pavletic ZS, et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor; association with donor characteristics. Blood 2001;98:1963-1970.
16. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-3389.
17. Pavletic ZS, Joshi SS, Pirruccello SJ, et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998;21: 33-41.
18. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001;19:3685-3691.
19. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415-419.
20. Mohty M, Kuentz M, Michailet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results if a randomized study. Blood 2002;100:3128-3134.
21. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001;98: 3221-3227.
22. Sullivan KM, Siadak MF, Witherspoon RO, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 1988;72:555-561.
23. Bensinger WI, Storb R. Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 2001;5:67-86.
24. Przepiorka D, Anderlini P, Salina R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-1700.
25. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant 2003;9:52-59.
26. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13-specific autoimmunity-a possible cause of chronic graft-versus-host disease. Transplantation 1996;61:600-609.
27. Biederman BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-2083.
28. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:674-682.
29. Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 1999;67:1478-1480.
30. Ratanatharathorn V, Bociek RG, Pavletic ZS, et al. Prior therapy with anti-CD20 chimeric antibody (Rituximab) may decrease the risk of acute graft-versus-host disease in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation. Blood 2000;96:391a (abstract 1688).
31. Handgretinger R, Lang P, Klingebiel T, Niethammer D. CD34 stem cell dose and development of extensive chronic graft-versus-host disease [letter]. Blood 2002;99:3874-3875.
32. Busca A, Locatelli F, Gargiulo A, et al. Clinical grading of oral involvement by chronic GVHD in a series of 104 consecutive adult patients. Blood 2001;98:397 (abstract 1670).
33. Stockschlader M, Hassan HT, Krog C, et al. Long-term follow-up of leukemia patients after related cryopreserved allogeneic bone marrow transplantation. Br J Haematol 1997;96:382-386.